D.Phil in Paediatrics
The Department of Paediatrics offers a number of opportunities for post-graduate research programmes, leading to a D.Phil in Paediatrics.
The Department has major interests in developmental immunology, infectious diseases of infancy and childhood, HIV infection and immune control, design, development and testing of vaccines, and in paediatric molecular genetics. Subject areas cover a large spectrum of paediatric medical, and scientific research.
Details of available DPhil projects can be found here.
OPEN FIELD-APPLICATIONS RECEIVED AFTER THE 10TH JANUARY 2020 DEADLINE
There is an open field period for applications received after the 10th January 2020 for entry in October 2020 and such applications will not be considered for the departmental studentships. Please contact individual supervisors to discuss your application and research proposal before submitting an application. Such applicants will need to have independently secured awards or private funding.
Applicants in the open field need to apply for the programme via the main University graduate application form.
To access the application form and application guide, please go to:
Application Guide; www.graduate.ox.ac.uk/applicationguide
Application Form; www.graduate.ox.ac.uk/applyonline
Course code (RD_PE1)
For further information, please see the Medical Sciences web pages: www.ox.ac.uk/admissions/graduate/courses/medical-sciences
CLINICAL DPHIL AT OXFORD
A doctorate is an important step in any clinical academic career. At any one time, numerous doctors are undertaking a DPhil at Oxford. Read more on the Oxford University Clinical Academic Graduate School DPhil page here.
For Oxford PGT students wishing to undertake a D.Phil in Paediatrics, please refer to www.graduate.ox.ac.uk/readmissions
Please contact firstname.lastname@example.org if you have any enquiries.
The Department of Paediatrics offers a variety of doctoral opportunities across its research themes. Take a look at the outlines of prospective DPhil projects - and please get in touch with the relevant supervisor to discuss the details.
The role of developmental stage specific programmes in infant/childhood leukaemia
Project outline: There have been remarkable advances in the treatment of childhood leukaemia, however some subtypes, such as infant leukaemia (iALL) have high relapse rates and poor survival; and more effective therapeutic strategies are needed. Natural history and molecular studies indicate that all cases of iALL originate in utero, it is distinct from childhood ALL, and most are caused by a balanced translocation of the MLL gene. The identity of the target prenatal B progenitor cell(s) in iALL is unclear. We have recently defined unique prenatal B cell developmental pathways and a possible target cell for iALL. These cells display a distinct, ontogeny-related gene expression pattern that is not seen in adult type progenitors, and they share many features with iALL cells. This project will explore whether these specific gene expression programmes provide a permissive cellular context for prenatal B-progenitor leukemia initiation, especially iALL, and whether they can be modified to develop new approaches to treatment.
Contact details: email@example.com
Applications by: 10th Jan 2020
Further information: The focus of our lab is to understand the link between human prenatal haematopoiesis and the origin and biology of childhood leukaemia, in particular infant acute lymphoblastic leukaemia (ALL). Infant ALL invariably originates before birth and MLL gene rearrangement is often sufficient to cause leukaemic transformation without additional genetic abnormalities. Our research aims to identify and characterise the poorly understood target cell population responsible for in utero initiation of infant ALL. This approach will allow us to identify pathways that can be targeted for future therapies in infant ALL.
Please note that applications for this project can also be submitted through the CRUK Oxford Centre DPhil in Cancer Science Programme for clinical and non-clinical tracks http://www.cancercentre.ox.ac.uk/graduate-studies/dphil-in-cancer-science-programme/
Efficacy and correlates of protection with a new paratyphoid vaccine in a controlled human infection model
Supervisor: Professor Andrew Pollard
The project will examine the potential efficacy of a new paratyphoid vaccine using a controlled human infection model. Human volunteers will be vaccinated with a new paratyphoid vaccine and then challenged with wild-type Salmonella Paratyphi by mouth in a bicarbonate solution. The volunteers will be closely monitored for 2 weeks, and treated either on developing infection or at 2 weeks if no infection is detected. We will examine antibody and cellular responses to ascertain the immune mechanisms associated with protection. The study will involve state-of-the-art cellular and serological techniques to provide new insights into immunity against this neglected disease.
Contact details: firstname.lastname@example.org
Applications by: 10th January 2020
Further information: The Oxford Vaccine Group is an interdisciplinary research environment with expertise form vaccine design and development through translation in to human studies, through phase 1-IV clinical evaluation and human challenge studies, and vaccine evaluation in the laboratory using state pf the art technology. Work on enteric fever is a major focus of the group with the aim of improving health among some of the most vulnerable populations through vaccine prevention of typhoid and paratyphoid.
Jin, C., Gibani MM, Moore M, Juel HB, Jones E, Meiring J, Harris V, Gardner J, Nebykova A, Kerridge SA, Hill J, Thomaides-Brears H, Blohmke CJ, Yu LM, Angus B and A. J. Pollard (2017). "Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial." Lancet 2017 Dec 2;390(10111):2472-2480
The impact of apnoea on brain activity in preterm infants
Supervisor: Dr Caroline Hartley
Project outline: Apnoea - the cessation of breathing - is a common pathology associated with prematurity. These potentially life-threatening events can result in reduced cerebral oxygenation and frequent apnoeas have been associated with long-term effects including reduced childhood cognitive ability. Brain activity drives brain development during the critical preterm period but the immediate impact of apnoeas on brain activity is not well understood. The aim of this project will be to characterise the relationship between apnoeas and brain activity in preterm infants, and how this changes with development. EEG (electroencephalography) and physiology will be recorded simultaneously, and signal processing approaches will be used and developed to fully characterise this relationship. This research will enhance our understanding of apnoeas, and ultimately seeks to improve outcomes for prematurely-born children.
Contact details: email@example.com
Applications by: 10th January 2020
Further information: The focus of the lab is to understand the impact of physiological instability on brain development in premature infants. 1 in every 10 babies are born prematurely; understanding and mitigating the long-term impact of premature birth is important to improve the lives of these children. We develop novel methodologies with the aim to provide a greater understanding of infant brain development and derive tools which can be translated to the clinical setting.
Intestinal inflammation and primary immunodeficiency
Supervisor: Professor Holm Uhlig
Project outline: Inflammatory bowel diseases (IBD) are a complex group of disorders with genetic predisposition. A minority of patients harbour extremely rare generic variants associated with Mendelian disorders. Maladaptation of the intestinal host microbial cross-talk towards intestinal bacteria can result in inflammatory bowel disease. Intestinal macrophages are key in this process since these cells phagocytose and remove translocating bacteria under homeostatic conditions without causing inflammation, whereas monocytes and monocyte derived macrophages can be major contributors of inflammatory cytokines if tolerance is broken. A genetically informed mechanistic concept of IBD suggests that immunosuppressive and anti-cytokine strategies should be combined with reinstalling of antimicrobial activity to induce and/or maintain remission. This project aims to characterise intestinal macrophage differentiation and antimicrobial activity in patients with Mendelian forms if intestinal inflammation. A functional genomic approach characterising the functional effects of rare variants via technologies such as single cell sequencing, proteomics and in vitro infection models will allow to understand key aspects of defective autophagy and resulting hyperinflammatory responses in those patients.
Contact details: Holm.Uhlig@ndm.ox.ac.uk
Applications by: 10th January 2020
Further information: The focus of the lab is to understand rare genetic defects that affect key mechanisms of the intestinal barrier function. We aim to understand patients that develop intestinal inflammation due to Mendelian disorders as proof of concept and understand how those mechanisms can direct novel diagnostics and treatments as well as inform on more common forms of intestinal inflammation (Uhlig & Powrie Annual Review Immunology 2018).
An evidence-based approach for treatment decision in pre-symptomatic patients with spinal muscular atrophy
Supervisors: Professor Laurent Servais
Project outline: There have been remarkable advances in the treatment of spinal muscular atrophy, with different approaches such as intrathecal antisens oligonucleotide, splicing modifiers, and gene therapy that are either approved, or on the road to approval. This has completely transformed the prognosis of spinal muscular atrophy type 1 from a fatal untreatable disease of babies to a treatable disease, which unfortunately remains associated with severe disability. However, pre-symptomatic treatment has been demonstrated to be transformative, and most babies treated before the symptoms present so far with a normal development. This has given rise to several newborn screening programs across the world.
It remains unclear how to identify patients who should be treated, since spinal muscular atrophy presents with a large phenotype, including adult forms. It is widely accepted that patients with 2 or 3 copies of the pseudo-gene SMN2 should be treated, but treating or not treating since birth patients with 4 copies remains a matter of debate.
We have organised an international workshop with key opinion world leader to identify the best methodology to base the decision on evidence. The aim of this PhD is to conduct the research. This requires the standarisation of the SMN2 copy numbers quantification, and the collection of data of patients certified with 4 copies. It also includes the identification of additional genetic biomarkers through the in-depth analysis of outliers.
This study will directly lead to the improvement of patient care, by identifying patients who should benefit from innovative - but expensive and sometimes burdensome - treatments.
Contact details: firstname.lastname@example.org
Applications by: 10th Jan 2020
Further information: The focus of our team is to help innovative therapies in the field of neuromuscular diseases to reach the patients' bedside as soon, and as efficiently, as possible. This incorporates the development of outcome measures, natural history studies, innovative trials designs, and identification of best responders.
In the field of spinal muscular atrophy, we have been instrumental in the conduct of clinical trials, and innovative outcome measures development and validation. We have developed one of the first genetic newborn screening that allowed so far to identify and to successfully treat 7 babies soon after birth and prevent the onset of symptoms.
DEVELOPMENT OF A NOVEL VACCINE TO PROTECT AGAINST PLAGUE: IMMUNE MECHANISMS OF IMMUNOGENICITY
Supervisor: Associate Professor Christine Rollier
Plague, caused by Yersinia pestis, is a highly contagious and virulent infectious disease. Since the 1980s, the number of human plague cases has increased in >25 countries. In 2013, The Center for Infectious Disease Research & Policy (CIDRAP) noted increased incidence since 2005 and plague is now considered a re-emerging infectious disease. We have developed novel vaccine candidates. The mechanism by which the antibodies block infection is not understood, and identifying this mechanism would support the clinical development of a novel vaccine. The aim of this project is to identify the antibody functions which are associated with protection against infection, by identifying the functional antibody profile induced by the novel protective vaccine as compared with those induced by less protective vaccine formulations. Moreover, the contribution of other aspects of the immune response may correlate with the immunogenicity and efficacy of the vaccine.The project will comprise a system serology approach, use of mouse models as well as human immunology, and will also explore the contribution of cellular and innate immune responses induced by the vaccine candidates, and how the vaccine delivery affects the immunogenicity.
Contact details: email@example.com
Applications by: 10th January 2020
Further information: The preclinical novel vaccine development team within the Oxford Vaccine Group is involved in the creation, design, preclinical and early clinical studies of new and improved vaccines against bacterial diseases and infectious diseases affecting children and vulnerable populations. Our current research activities, funded by the Medical Research Council, Innovate UK, the Oxford Biomedical Research Centre, and other funders and charities, include vaccine development against caspular group B meningococcus, plague, Q fever, enteric fever and pertussis, using state of the art technology. Several of our projects involve creation of intellectual property prior to publishing.
Daniels-Treffandier H, de Nie K, Marsay L, Dold C, Sadarangani M, Reyes-Sandoval A, Langford PR, Wyllie D, Hill F, Pollard AJ, Rollier CS. Impact of Reducing Complement Inhibitor Binding on the Immunogenicity of Native Neisseria meningitidis Outer Membrane Vesicles. PLoS One. 2016 Feb 12;11(2):e0148840.
Exploring the early response to (para)typhoid exposure in a human challenge model of infection
Student name: Amber Barton
Description: Several plasma cytokines have been found to transiently increase around 12 hours after healthy volunteers are experimentally exposed to Salmonella Typhi, regardless of whether they go on to develop signs of infection. This raises a number of questions, including the identity and location of the cells producing these cytokines, whether we can detect other immunological signatures of exposure, and whether such signatures differ between those who become infected and those who remain well. In this project these questions are being addressed using whole blood transcriptional analysis. Early differences in the transcriptome between individuals who remain well and those who develop disease have indicated genes which might be involved in protection. Furthermore, gene set enrichment analysis of blood transcriptional changes occurring 12 h post-exposure has allowed characterisation of early cellular responses, the significance of which is being investigated further with in vitro experiments.
Source of funding: St Cross Paediatrics Scholarship (Department of Paediatrics and St Cross College), with project support from Wellcome Trust and the Bill and Melinda Gates Foundation.
Blohmke, C. et al. (2016) Interferon-driven alterations of the host’s amino acid metabolism in the pathogenesis of typhoid fever. Journal of Experimental Medicine.
Evaluating the effect of immunisation with capsular group B meningococcal vaccines on meningococcal carriage
Student name: Jeremy Carr
Description: Capsular group B meningococcal (MenB) vaccines provide direct protection against invasive MenB disease, however the effect on herd protection is not known. This study will evaluate the influence of MenB immunisation on oropharyngeal carriage in teenagers, and consequently the potential for these vaccines to disrupt transmission and provide broad community protection against MenB disease. Given the potential for immunisation with the subcapsular protein antigens in MenB vaccines to impact on the carriage of non-MenB pathogenic and commensal Neisseria species, carriage rates of these organisms will also be evaluated. Understanding the influence of MenB protein-based vaccines on herd protection will inform current vaccine policy and future vaccine development.
Source of funding: University of Oxford; Clarendon Scholarship; National Institute for Health Research; Department of Health.
Further information: https://beontheteam.web.ox.ac.uk/
Assessing the immune mechanisms underlying the immunogenicity to meningococcal group B vaccines
Student name: Dylan Sheerin
Description: The Gram-negative bacterium Neisseria meningitidis is the causative agent of invasive meningococcal disease (IMD), a severe bacterial infection which occurs predominantly in infants within the first years of life. Two meningococcus group B (MenB) vaccines have been licensed, but both have significant drawbacks. A novel MenB vaccine has been developed at the Oxford Vaccine Group, based on a viral vector. The vaccine candidate induced strong and persistent protective immune responses in mice after a single dose, and a phase I trial to assess its safety and immunogenicity in healthy adults is ongoing. The D.Phil student is working on understanding the mechanisms which underlie the responses induced by these distinct vaccines at the genetic, cellular and systems level, and the results will contribute to the rational design of future vaccine candidates for MenB and other bacterial diseases.
Source of funding: Medical Research Council
Further information: Currently in second year.
RaPaed-TB: Evaluation of New Diagnostics in Childhood TB
Student name: Laura Olbrich
Description: Globally, children account for an estimated one million TB cases and more then 200,000 deaths due to TB per year. The main challenge is adequate and timely diagnosis as currently available diagnostic tests fail to diagnose the majority of children with TB. New testing strategies are therefore urgently needed. In a prospective, multi-country clinical study in four African countries and in India, diagnostic performance data on a number of promising novel assays and sampling strategies will be generated. In addition, the study will derive diagnostic and screening algorithms for TB using existing and these novel tests.
Source of funding: EDCTP